Literature DB >> 27456825

The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases.

Gholamreza Azizi, Hassan Abolhassani, Mohammad Hosein Asgardoon, Javad Rahnavard, Majid Zaki Dizaji, Reza Yazdani, Javad Mohammadi, Asghar Aghamohammadi1.   

Abstract

Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Immunoglobulin; infection; primary antibody deficiency; primary immunodeficiency diseases

Year:  2016        PMID: 27456825     DOI: 10.2174/1871530316666160724214418

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  2 in total

1.  Respiratory Complications in Patients with Hyper IgM Syndrome.

Authors:  Bobak Moazzami; Reza Yazdani; Gholamreza Azizi; Fatemeh Kiaei; Mitra Tafakori; Mohammadreza Modaresi; Rohola Shirzadi; Seyed Alireza Mahdaviani; Mahsa Sohani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2019-06-11       Impact factor: 8.317

2.  Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID).

Authors:  Ali Zarezadeh Mehrabadi; Nazanin Aghamohamadi; Hassan Abolhassani; Asghar Aghamohammadi; Nima Rezaei; Reza Yazdani
Journal:  J Clin Immunol       Date:  2022-01-27       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.